7TM Pharma Raises EUR 16.5 Million in Financing Round

7TM Pharma A/S has raised EUR 16.5 million in a new financing round. The financing round included SR One Limited, SR One, who led the investment with strong support from the company's existing investors. SR One is GlaxoSmithKline's independent corporate health care venture fund.

The fresh capital will help accelerate the company's drug discovery and drug development programs, primarily further clinical development of the drug candidates Obinepitide, TM30338, and TM30339, both for the treatment of obesity.

For further information please contact:

Mette Kirstine Agger,

CEO

Tel: +45 39 25 77 77

E-mail: agger@7tm.com

Or visit: www.7tm.com

Home > News & Events > News > 7TM Pharma Raises EUR 16.5 Million in Financing Round
Last updated: 2007-06-29

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

7TM Pharma A/S

7TM Pharma A/S is a privately held company, incorporated in 2000 as spin out from University of Copenhagen by internationally recognized pioneers in 7TM receptor research, Professor Thue W. Schwartz and Dr. Christian E. Elling alongside with industry-experienced Mette Kirstine Agger (CEO). The comp...